Home › Trials › NCT07039110

Risankizumab for improving quality of life in adults with moderate-to-severe plaque psoriasis

The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)

Observational AbbVie · NCT07039110

See if risankizumab improves quality of life for adults with moderate-to-severe plaque psoriasis treated in routine clinical care.

Quick facts

Study typeObservational
Enrollment700 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsrisankizumab
Locations70 sites (Edmonton, Alberta and 69 other locations)
Trial IDNCT07039110 on ClinicalTrials.gov

What this trial studies

This is a multicenter, observational follow-up of roughly 700 adults prescribed risankizumab according to local labels and routine practice. Participants will receive risankizumab as their physician directs and will be followed for up to 2.5 years with visits scheduled as part of normal clinical care. Data collection focuses on patient-reported quality of life and routine clinical information without additional experimental interventions. The study excludes patients currently on other biologics or certain small-molecule therapies and those recently in other clinical studies.

Who should consider this trial

Good fit: Adults with a confirmed diagnosis of moderate-to-severe plaque psoriasis for whom the treating physician has independently decided to prescribe risankizumab and who are not currently on other biologic or specified small-molecule psoriasis therapies.

Not a fit: Patients currently receiving other biologic or small-molecule psoriasis treatments, those treated for a sleep disorder, or those recently enrolled in other clinical studies may not be eligible or derive direct benefit from this observational program.

Why it matters

Potential benefit: If successful, the study could show that risankizumab leads to meaningful quality-of-life improvements for patients in everyday clinical settings, helping inform treatment decisions.

How similar studies have performed: Randomized controlled trials have demonstrated risankizumab improves psoriasis severity and patient-reported quality of life, but large long-term real-world QoL data are more limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
* Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
* Decision to treat with risankizumab is made prior to and independently of study participation.

Exclusion Criteria:

* History of a sleep disorder diagnosis which the patient is currently being treated for.
* Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
* Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Where this trial is running

Edmonton, Alberta and 69 other locations

+20 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Plaque PsoriasisModerate to Severe Plaque PsoriasisRisankizumab
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.